This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Diagnosis of retinoblastoma

Authoring team

Majority of cases present within the first 2 years of life (at a mean age of 18 months) (1)

  • hereditary retinoblastoma is seen at a younger age than the non-hereditary disease
  • in patients presenting with unilateral retinoblastoma
    • if younger than 1 year - suspect hereditary disease
    • if older children - more likely to have the nonhereditary form of the disease (2)

Patients who presents with symptoms and signs of retinoblastoma should have a red reflex test done to determine whether the child needs to be referred for a specialist examination.

  • normal red reflex- no referral
  • red reflex absent
    • obvious +/-asymmetry - urgent referral
    • unsure/difficult assessment - Paediatric Ophthalmology Primary Care Clinic referral
  • red reflex abnormal - "urgent" referral (3).

Further evaluation of tumour is carried out with the following examinations:

  • ultrasonography of the eyes - to detect intralesional calcification,
  • magnetic resonance imaging (MRI) of the brain and orbits - to check for extraocular extension and to rule out trilateral retinoblastoma in patients with germline mutations (4,5)
  • lumbar puncture with cerebrospinal fluid analysis, bone marrow aspiration, bone scan - indicated in advanced intraocular disease or with evidence of extra-ocular disease at presentation

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.